Publication:
The clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients

dc.contributor.authorsEren, P. A.; Turan, K.; Berber, I.; Canbakan, M.; Kara, M.; Tellioglu, G.; Bugan, U.; Sevinc, C.; Turkmen, F.; Titiz, M. I.
dc.date.accessioned2022-03-12T17:46:38Z
dc.date.accessioned2026-01-11T15:20:30Z
dc.date.available2022-03-12T17:46:38Z
dc.date.issued2009
dc.description.abstractBackground: The calcium sending receptor (CaSR) allows parathyroid and kidney tubular cells to regulate PTH secretion and tubular calcium reabsorption. In the present report, we examined the relationship between CaSR gene polymorphisms and parathyroid CaSR expression and serum calcium/parathyroid hormone (PTH) levels and clinical progress in ESRD patients in the Turkish population. Methods: We genotyped the CaSR R990G and Q1011E variants in 192 end-stage renal disease (ESRD) patients by allele-specific PCR. CaSR expression in parathyroid tissues of operated 33 patients was quantified with quantitative reverse transcription-PCR. Results: Compared with other genotypes, the ratio of both codon 990-AA and 1011-CC polymorphisms was found higher in operated patients (p = 0.001). In the total patient group PTH levels were found higher in patients with CC1011 genotype than those with CG(1011) (1015.15 +/- 925.41 pg/ml; 523.84 +/- 544.6 pg/ml, respectively, p = 0.002). There were statistically important higher Ca2+ levels in the AA(990) allele carrying cases than AG(990) positive ones (9.3 +/- 1.0 mg/dl vs. 8.8 +/- 0.9, p = 0.006). On the other hand, the expression of CaSR in parathyroid tissue was found inversely proportional with serum PTH level (r = -0.71). Conclusion: Present data suggest that co-presence of CaSR gene AA(990) and CC1011 alleles is a possible risk factor for bad prognosis in secondary hyperparathyroidism. Patients carrying this genotype have tendency to require operation early in their medical therapy period and need postoperative close follow up for possible recurrences.
dc.identifier.doidoiWOS:000269080900002
dc.identifier.issn0301-0430
dc.identifier.pubmed19640368
dc.identifier.urihttps://hdl.handle.net/11424/229481
dc.identifier.wosWOS:000269080900002
dc.language.isoeng
dc.publisherDUSTRI-VERLAG DR KARL FEISTLE
dc.relation.ispartofCLINICAL NEPHROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectend-stage renal disease
dc.subjectCaSR
dc.subjectpolymorphisms
dc.subjectsecondary hyperparathyroidism
dc.subjectPTH
dc.subjectEXTRACELLULAR CA2+-SENSING RECEPTOR
dc.subjectFAMILIAL HYPOCALCIURIC HYPERCALCEMIA
dc.subjectNEONATAL SEVERE HYPERPARATHYROIDISM
dc.subjectPTH SECRETION
dc.subjectMOLECULAR-CLONING
dc.subjectHORMONE SECRETION
dc.subjectIN-VITRO
dc.subjectPROTEIN
dc.subjectLOCALIZATION
dc.subjectHEMODIALYSIS
dc.titleThe clinical significance of parathyroid tissue calcium sensing receptor gene polymorphisms and expression levels in end-stage renal disease patients
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage121
oaire.citation.issue2
oaire.citation.startPage114
oaire.citation.titleCLINICAL NEPHROLOGY
oaire.citation.volume72

Files